PriceTargets.com logo

ProSomnus - OSA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 107.90%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.81 As of 06/2/2023 12:11 PM ET
▼ -0.02 (-0.41%)

This chart shows the closing price for OSA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ProSomnus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OSA

Analyst Price Target is $10.00
▲ +107.90% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ProSomnus in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 107.90% upside from the last price of $4.81.

This chart shows the closing price for OSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in ProSomnus.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2023Roth CapitalReiterated RatingBuyLow
4/3/2023Craig HallumInitiated CoverageBuy$10.00Low
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
ProSomnus logo
ProSomnus, Inc. manufactures and sells precision oral appliance therapy devices for the treatment of obstructive sleep apnea. The company is headquartered in Pleasanton, California.
Read More

Today's Range

Now: $4.81
Low: $4.81
High: $4.86

50 Day Range

MA: $5.08
Low: $4.83
High: $5.23

52 Week Range

Now: $4.81
Low: $4.57
High: $9.41

Volume

4,471 shs

Average Volume

7,087 shs

Market Capitalization

$77.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.26

Frequently Asked Questions

What sell-side analysts currently cover shares of ProSomnus?

The following Wall Street analysts have issued reports on ProSomnus in the last twelve months: Craig Hallum, and Roth Capital.
View the latest analyst ratings for OSA.

What is the current price target for ProSomnus?

1 Wall Street analysts have set twelve-month price targets for ProSomnus in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 107.9%. Craig Hallum has the highest price target set, predicting OSA will reach $10.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $10.00 for ProSomnus in the next year.
View the latest price targets for OSA.

What is the current consensus analyst rating for ProSomnus?

ProSomnus currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OSA will outperform the market and that investors should add to their positions of ProSomnus.
View the latest ratings for OSA.

What other companies compete with ProSomnus?

Other companies that are similar to ProSomnus include Delcath Systems, Lyra Therapeutics, Neuronetics, Meihua International Medical Technologies and Lucid Diagnostics. Learn More about companies similar to ProSomnus.

How do I contact ProSomnus' investor relations team?

ProSomnus' physical mailing address is Suite A-2F 555 Shihui Road Songjiang District, Shanghai F4, 201100. The company's listed phone number is 844-537-5337 and its investor relations email address is [email protected]. The official website for ProSomnus is www.ProSomnus.com. Learn More about contacing ProSomnus investor relations.